From: Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
Patient number | Clinical outcome | Time to complete response (weeks) | Follow-up period (months) | Maximun dose received (mg) | Relapse | Dose at relapse |
---|---|---|---|---|---|---|
1 | CR | 10 | 15 | 5 | Yes | 5 mg twice weekly |
2 | CR | 4 | 12 | 5 | Yes | 5 mg three times weekly |
3 | Withdrawn | - | - | 5 | - | - |
4 | CR | 3 | 12 | 5 | Yes | 5 mg alternate days |
5 | CR | 36 | 19 | 5 | - | - |
6 | CR | 4 | 17 | 5 | No | - |
7 | CR | 11 | 18 | 5 | No | - |
8 | CR | 2 | 7 | 5 | Yes | 5 mg alternate days |
9 | PR | - | 15 | 10 | - | - |
10 | CR | 7 | 10 | 5 | Yes | 5 mg alternate days |
11 | CR | 4 | 30 | 5 | Yes | 5 mg twice weekly |
12 | CR | 4 | 25 | 5 | Yes | 5 mg alternate days |
13 | PR | - | 8 | 5 | - | - |
14 | CR | 12 | 17 | 5 | Yes | 5 mg three times weekly |
15 | CR | 2 | 10 | 5 | Yes | 5 mg alternate days |